A cheap antidepressant reduces the risk of hospitalisation in Covid-19 outpatients that are at higher risk of severe disease, a large study has found.
Researchers in a peer-reviewed study published in The Lancet Global Health found that fluvoxamine, which is used to treat depression and obsessive-compulsive disorders, reduced the need for retention in a Covid emergency setting or transfer to another hospital.
It is the largest randomised trial to date to assess the effectiveness of the drug in Covid outpatients, and follows earlier promising evidence.
您已閱讀19%（555字），剩余81%（2376字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。